Clinical Trial Update: Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety and initial efficacy of Obatoclax Mesylate in combination with Bortezomib for relapsed or refractory mantle cell lymphoma; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Obatoclax mesylate (GX15-070MS) (obatoclax mesylate)

Snippet

Sponsor: Gemin X | Conditions: Mantle-Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED